CDMO News
Skyepharma Advances Oncology Contract Manufacturing with French Facility Launch
Skyepharma has marked six months of activity at its MMPP (Medicines to be Handled with Particular Care) facility, dedicated to the development and production of high-potency oral oncology drugs. The French CDMO has shared early achievements from the site, located in
16 May 2025
